The yet-to-be peer-reviewed results also show the vaccine, being trialled with the anticipated involvement of 20 people aged 60 and over, was generally safe and well-tolerated. London: A COVID-19 vaccine booster aimed at tackling multiple coronavirus variants shows promise in inducing a comprehensive immune response, early data suggests. The initial phase one clinical data shows the vaccine has strong levels …
London: A COVID-19 vaccine booster aimed at tackling multiple coronavirus variants shows promise in inducing a comprehensive immune response, early data suggests. The initial phase one clinical data shows the vaccine has strong levels of neutralising antibodies, similar to approved mRNA vaccines, but at up to a 10-fold lower dose in the first 10 individuals. "These initial data with samRNA …
A Covid-19 vaccine booster aimed at tackling multiple coronavirus variants shows promise in inducing a comprehensive immune response, early data suggests. The initial phase one clinical data shows the vaccine has strong levels of neutralising antibodies, similar to approved mRNA vaccines, but at up to a 10-fold lower dose in the first 10 individuals. "These initial data with samRNA Covid …
)
